Compare Apollo Global Management Ord Shs (APO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Novavax Inc — how do they compare? Apollo Global Management Ord Shs trades at $138.13 (market cap $82.84B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Apollo Global Management Ord Shs is far larger — about 63.2× Novavax Inc's market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| APO | NVAX | |
|---|---|---|
Market Cap | $82.84B | $1.31B |
Sector | Financials | Health |
52-Week High | $152.70 | $11.19 |
52-Week Low | $100.30 | $6.22 |
Enterprise Value | -$168.65B | $889.30M |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $138.79, up 5.13% today, near its 52-week high. The stock shows a bullish technical trend with strong analyst support, including 23 buy ratings and a consensus price target of $151.50. Recent Q2 2026 earnings of $2.11 per share missed estimates, but revenue growth and record assets under management of $1.05 trillion highlight operational strength. The company continues expanding in AI infrastructure deals, as noted in recent news.
Outlook remains positive given robust fundraising and perpetual capital growth, though risks include expense pressures and market volatility. The high P/E ratio of 49.92 suggests premium valuation, requiring sustained earnings growth to justify upside. Investors should weigh strong institutional sentiment against execution risks in a competitive asset management landscape.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
